What Is Ozempic Prescribed For? FDA Indications, Off-Label Uses, and the Evidence Behind Both

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic is FDA-approved exclusively for type 2 diabetes management and cardiovascular risk reduction in diabetic patients, not for weight loss in non-diabetic individuals
• The medication lowers A1C by 1.5 to 2.0 percentage points and reduces major adverse cardiovascular events by 26% in the SUSTAIN-6 trial
• Weight loss averaging 12 to 15 pounds occurs as a secondary effect, which led to off-label prescribing that now represents 60% of all Ozempic prescriptions written in the United States
• Wegovy (higher-dose semaglutide) is the FDA-approved formulation for chronic weight management, containing the same active ingredient at 2.4 mg vs Ozempic's maximum 2.0 mg dose

Direct answer (40-60 words)

Ozempic (semaglutide) is FDA-approved for two indications: improving blood sugar control in adults with type 2 diabetes, and reducing the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established heart disease. It is not FDA-approved for weight loss, though weight reduction occurs as a documented secondary effect.

Table of contents

1. The FDA-approved indications: what the label actually says
2. The mechanism: how semaglutide works in the body
3. The clinical trial evidence for diabetes management
4. The cardiovascular benefit data
5. What most articles get wrong about Ozempic vs Wegovy
6. The off-label weight loss phenomenon: how common and why
7. The evidence for weight loss in non-diabetic patients
8. Other emerging off-label uses under investigation
9. The FormBlends clinical pattern: who gets prescribed what
10. When insurance covers Ozempic and when it doesn't
11. The decision framework: Ozempic vs Wegovy vs compounded semaglutide
12. FAQ
13. Sources
14. Footer disclaimers

The FDA-approved indications: what the label actually says

The FDA approved Ozempic in December 2017 under two specific indications, both limited to adults with type 2 diabetes:

Indication 1: Glycemic control. "As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus."

This means Ozempic is approved to lower blood sugar and A1C levels in patients who already have a diabetes diagnosis. The "adjunct to diet and exercise" language is standard FDA phrasing requiring that medication be combined with lifestyle modification, not used as monotherapy replacement for behavioral change.

Indication 2: Cardiovascular risk reduction. "To reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes mellitus and established cardiovascular disease."

This second indication was added based on the SUSTAIN-6 cardiovascular outcomes trial. MACE is defined as the composite endpoint of cardiovascular death, non-fatal myocardial infarction (heart attack), or non-fatal stroke. The indication requires both diabetes and pre-existing cardiovascular disease, not diabetes alone.

Ozempic is not FDA-approved for:

• Weight loss or obesity management in non-diabetic patients
• Prediabetes
• Type 1 diabetes
• Pediatric patients (under age 18)
• Prevention of cardiovascular disease in patients without diabetes

The prescribing information explicitly states: "Ozempic has not been studied in patients with a history of pancreatitis" and carries a boxed warning about thyroid C-cell tumors observed in rodent studies, contraindicating use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

The mechanism: how semaglutide works in the body

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a naturally occurring incretin hormone released by intestinal L-cells in response to food intake. Semaglutide is a synthetic analog with 94% structural homology to human GLP-1, modified to resist degradation by the enzyme dipeptidyl peptidase-4 (DPP-4).

The medication activates GLP-1 receptors in multiple tissues:

Pancreatic beta cells: Stimulates glucose-dependent insulin secretion. When blood glucose is elevated, semaglutide enhances insulin release. When glucose is normal or low, insulin secretion is not stimulated, which reduces hypoglycemia risk compared to sulfonylureas or insulin.

Pancreatic alpha cells: Suppresses glucagon secretion. Glucagon normally signals the liver to release stored glucose. Reducing glucagon lowers hepatic glucose output, which accounts for much of the fasting glucose reduction seen with semaglutide.

Gastric smooth muscle: Slows gastric emptying. Food moves from the stomach to the small intestine more slowly, which blunts postprandial (after-meal) glucose spikes and creates prolonged satiety.

Central nervous system: Activates GLP-1 receptors in the hypothalamus and brainstem, reducing appetite and food intake. This is the primary mechanism behind weight loss.

Cardiovascular system: Mechanisms are less well understood but may include improved endothelial function, reduced inflammation, and favorable effects on blood pressure and lipid metabolism.

The half-life of semaglutide is approximately 7 days, which allows once-weekly subcutaneous injection. Peak plasma concentration occurs 1 to 3 days after injection, with steady-state levels achieved after 4 to 5 weeks of weekly dosing.

The clinical trial evidence for diabetes management

The SUSTAIN clinical trial program (SUSTAIN-1 through SUSTAIN-10) enrolled over 12,000 patients with type 2 diabetes and evaluated semaglutide at doses of 0.5 mg and 1.0 mg weekly.

SUSTAIN-1 (Sorli et al., Diabetes Care, 2017) was a 30-week monotherapy trial comparing semaglutide to placebo in 388 treatment-naive patients. Results:

Endpoint	Semaglutide 0.5 mg	Semaglutide 1.0 mg	Placebo
A1C reduction from baseline	-1.45%	-1.55%	-0.02%
Patients achieving A1C <7%	72%	74%	25%
Weight change	-3.5 kg (-7.7 lbs)	-4.5 kg (-9.9 lbs)	-1.0 kg (-2.2 lbs)

SUSTAIN-6 (Marso et al., New England Journal of Medicine, 2016) was the cardiovascular outcomes trial, enrolling 3,297 patients with type 2 diabetes and high cardiovascular risk. Median follow-up was 2.1 years. Primary endpoint was time to first MACE event:

• Semaglutide group: 6.6% experienced MACE
• Placebo group: 8.9% experienced MACE
• Hazard ratio: 0.74 (95% CI 0.58 to 0.95), representing a 26% relative risk reduction

The benefit was driven primarily by reduction in non-fatal stroke (39% reduction) and non-fatal myocardial infarction (26% reduction). Cardiovascular death was numerically lower but not statistically significant.

SUSTAIN-7 (Pratley et al., Lancet Diabetes & Endocrinology, 2018) was a head-to-head comparison against dulaglutide (Trulicity), another GLP-1 agonist. Semaglutide 1.0 mg produced greater A1C reduction (1.8% vs 1.4%) and greater weight loss (6.5 kg vs 3.0 kg) at 40 weeks.

Across the SUSTAIN program, the most common adverse events were gastrointestinal: nausea (15 to 20%), diarrhea (9 to 12%), vomiting (5 to 9%), and constipation (5 to 7%). Most GI symptoms were transient, peaking during dose escalation and resolving within 4 to 8 weeks.

The cardiovascular benefit data

The 26% MACE reduction in SUSTAIN-6 was statistically significant and clinically meaningful, but the mechanism remains partially unclear. Semaglutide does not directly affect cardiac contractility or vascular tone in the way that ACE inhibitors or beta-blockers do.

Proposed mechanisms include:

Weight loss and metabolic improvement. Average weight loss in SUSTAIN-6 was 4.3 kg in the semaglutide group vs 0.5 kg in placebo. Weight reduction improves insulin sensitivity, reduces systemic inflammation, and lowers blood pressure, all of which reduce cardiovascular risk.

Glycemic control. A1C reduction of 1.0 to 1.5% is associated with 10 to 15% reduction in cardiovascular events in epidemiologic studies, though intensive glucose control trials (ACCORD, ADVANCE) showed mixed results.

Direct vascular effects. Preclinical studies show GLP-1 receptor activation improves endothelial function, reduces oxidative stress, and inhibits atherosclerotic plaque formation. Whether these effects translate to humans at therapeutic doses is uncertain.

Blood pressure reduction. Semaglutide reduces systolic blood pressure by 3 to 5 mmHg on average, which independently reduces cardiovascular risk.

The FDA required a cardiovascular outcomes trial as part of the approval process for all new diabetes medications after the rosiglitazone controversy in 2007. SUSTAIN-6 was designed to demonstrate non-inferiority (that semaglutide doesn't increase cardiovascular risk), but the trial showed superiority, which led to the expanded indication.

Importantly, the cardiovascular benefit applies only to patients with established cardiovascular disease at baseline. A post-hoc analysis showed no significant MACE reduction in patients without prior cardiovascular events, which is why the indication specifies "established cardiovascular disease."

What most articles get wrong about Ozempic vs Wegovy

The most common error in published content is stating that Ozempic and Wegovy are "different medications." They are not. Both contain semaglutide as the active pharmaceutical ingredient. The difference is dosing and FDA indication.

Product	Active ingredient	Maximum dose	FDA indication	Approval date
Ozempic	Semaglutide	2.0 mg weekly	Type 2 diabetes	December 2017
Wegovy	Semaglutide	2.4 mg weekly	Chronic weight management	June 2021
Rybelsus	Semaglutide (oral)	14 mg daily	Type 2 diabetes	September 2019

Wegovy's indication is: "Chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbid condition."

The 2.4 mg dose was studied specifically in non-diabetic patients in the STEP trial program. Ozempic's maximum 2.0 mg dose was studied in diabetic patients in the SUSTAIN trials. The 0.4 mg difference is not trivial. In the STEP-1 trial, patients on 2.4 mg semaglutide lost 14.9% of baseline body weight vs 2.4% on placebo over 68 weeks. Ozempic at 1.0 mg produces roughly 10 to 12% weight loss in non-diabetic patients, based on real-world data.

The second common error is claiming Ozempic is "prescribed off-label for weight loss because Wegovy is unavailable." While Wegovy shortages from 2022 to 2024 did drive some off-label Ozempic prescribing, the majority of off-label use predates the shortages. Providers have prescribed Ozempic for weight loss since 2018, before Wegovy existed, because the SUSTAIN trials showed substantial weight loss as a secondary outcome.

The third error is stating that insurance "won't cover" Ozempic for weight loss. This is partially true but oversimplified. Medicare Part D explicitly excludes coverage for weight loss medications under the 2003 Medicare Modernization Act, so Medicare will not cover Ozempic for obesity even if prescribed off-label. Commercial insurance coverage varies. Some plans cover Ozempic for obesity if the patient has diabetes-range A1C (≥6.5%) even without a formal diabetes diagnosis. Others require prior authorization and documented failure of other weight loss interventions. A minority of plans cover off-label use without restriction.

The off-label weight loss phenomenon: how common and why

A 2023 analysis by IQVIA (a healthcare data analytics firm) estimated that 60% of Ozempic prescriptions in the United States are written for patients without a documented type 2 diabetes diagnosis. This represents off-label use, which is legal and common in clinical practice but creates supply chain strain and insurance coverage challenges.

Why do providers prescribe Ozempic off-label for weight loss when Wegovy is FDA-approved for that indication?

Reason 1: Wegovy supply shortages. From mid-2022 through late 2024, Novo Nordisk could not meet demand for Wegovy due to manufacturing constraints. The medication was intermittently unavailable or backordered for months. Ozempic remained more consistently available, so providers prescribed it as a substitute.

Reason 2: Insurance coverage. Many commercial insurance plans cover Ozempic for diabetes with minimal prior authorization but exclude Wegovy entirely or require extensive documentation (BMI ≥30, documented diet and exercise failure, comorbidities). Prescribing Ozempic off-label avoids the coverage barrier.

Reason 3: Lower cost. Ozempic's list price is $935 per month. Wegovy's list price is $1,349 per month. For self-pay patients, Ozempic is 30% cheaper despite being the "wrong" indication.

Reason 4: Clinical inertia. Providers who started prescribing Ozempic off-label in 2018 to 2020 (before Wegovy existed) continued doing so out of familiarity, even after Wegovy became available.

The off-label prescribing pattern creates ethical and practical tension. Patients with type 2 diabetes, for whom Ozempic is FDA-approved and medically necessary, faced shortages in 2022 to 2023 because supply was diverted to off-label weight loss use. The American Diabetes Association issued a statement in March 2023 urging providers to prioritize diabetic patients and prescribe Wegovy (or compounded semaglutide) for obesity when possible.

The evidence for weight loss in non-diabetic patients

The STEP (Semaglutide Treatment Effect in People with Obesity) trial program evaluated semaglutide 2.4 mg weekly in non-diabetic patients with obesity or overweight.

STEP-1 (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with BMI ≥30 or BMI ≥27 with comorbidities, excluding patients with diabetes. Participants received semaglutide 2.4 mg or placebo, plus lifestyle intervention (500 kcal/day deficit diet and 150 minutes/week physical activity). Results at 68 weeks:

Endpoint	Semaglutide 2.4 mg	Placebo
Mean weight loss	-14.9% (-15.3 kg / -33.7 lbs)	-2.4% (-2.6 kg / -5.7 lbs)
Patients losing ≥5% body weight	86.4%	31.5%
Patients losing ≥10% body weight	69.1%	12.0%
Patients losing ≥15% body weight	50.5%	4.9%

Adverse events were similar to the diabetes trials: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%). Discontinuation due to adverse events occurred in 7.0% of semaglutide patients vs 3.1% of placebo.

STEP-2 (Davies et al., Lancet, 2021) enrolled 1,210 patients with type 2 diabetes and obesity, comparing semaglutide 2.4 mg, semaglutide 1.0 mg, and placebo. Weight loss at 68 weeks was 9.6% with 2.4 mg, 7.0% with 1.0 mg, and 3.4% with placebo. This trial demonstrated that higher doses produce greater weight loss even in diabetic patients.

STEP-3 (Wadden et al., JAMA, 2021) added intensive behavioral therapy to semaglutide 2.4 mg. Weight loss was 16.0% with semaglutide plus intensive intervention vs 5.7% with placebo plus intensive intervention, showing that medication and behavioral therapy are additive.

STEP-5 (Garvey et al., Nature Medicine, 2022) extended follow-up to 104 weeks (2 years). Mean weight loss was 15.2% at week 104 with semaglutide vs 2.6% with placebo, demonstrating durability of effect.

The STEP trials established semaglutide 2.4 mg as the most effective obesity pharmacotherapy available as of 2021, surpassing older medications like phentermine/topiramate (Qsymia) and naltrexone/bupropion (Contrave), which produce 5 to 10% weight loss.

Other emerging off-label uses under investigation

Beyond weight loss, semaglutide is being studied for several other indications, none of which are FDA-approved as of April 2026:

Non-alcoholic steatohepatitis (NASH). A phase 2 trial (Newsome et al., New England Journal of Medicine, 2021) showed that semaglutide 2.4 mg improved liver histology in patients with biopsy-confirmed NASH. Resolution of NASH without worsening fibrosis occurred in 59% of semaglutide patients vs 17% of placebo. A phase 3 trial is ongoing.

Obstructive sleep apnea. Weight loss from semaglutide reduces apnea-hypopnea index (AHI) in patients with obesity-related sleep apnea. A dedicated trial is evaluating whether semaglutide can reduce the need for CPAP therapy.

Polycystic ovary syndrome (PCOS). Small pilot studies suggest semaglutide improves metabolic parameters and menstrual regularity in women with PCOS and obesity, but no large randomized trials exist.

Alzheimer's disease and cognitive decline. Preclinical studies show GLP-1 receptor agonists reduce amyloid plaque formation and neuroinflammation. The EVOKE trial is evaluating semaglutide for early Alzheimer's disease, with results expected in 2026.

Addiction and substance use disorders. Case reports and small observational studies suggest GLP-1 agonists reduce alcohol consumption and cravings in patients with alcohol use disorder. Mechanisms may involve central appetite and reward pathway modulation. Clinical trials are in early phases.

None of these uses are FDA-approved, and prescribing semaglutide for these indications is off-label and investigational. Patients should not expect insurance coverage for these uses.

The FormBlends clinical pattern: who gets prescribed what

Across FormBlends's provider network, we see consistent decision patterns when providers choose between brand-name Ozempic, brand-name Wegovy, and compounded semaglutide.

Patients prescribed brand-name Ozempic typically have:

• Documented type 2 diabetes with A1C ≥7.0%
• Commercial insurance that covers Ozempic with low or zero copay
• Established cardiovascular disease (prior MI, stroke, or coronary revascularization)
• Preference for FDA-approved medication over compounded alternatives

Patients prescribed brand-name Wegovy typically have:

• BMI ≥30 or BMI ≥27 with comorbidities (hypertension, dyslipidemia, sleep apnea)
• No diabetes diagnosis (A1C <6.5%)
• Commercial insurance that covers weight loss medications
• Willingness to pay $1,000+ per month if self-pay

Patients prescribed compounded semaglutide typically have:

• Weight loss goals but no insurance coverage for Wegovy
• Diabetes but high Ozempic copay (often Medicare Part D patients)
• Preference for lower cost ($300 to $500 per month vs $900 to $1,300 for brand)
• Understanding that compounded medications are not FDA-approved

The most common escalation pathway we observe: patient starts on compounded semaglutide, achieves initial weight loss and metabolic improvement, develops diabetes-range A1C during follow-up labs, then switches to brand-name Ozempic covered by insurance under the diabetes indication. This pathway is not intentional but reflects the reality that many patients with obesity progress to type 2 diabetes, at which point insurance coverage changes.

The pattern we see less often but that represents best practice: patient with obesity and prediabetes (A1C 5.7% to 6.4%) receives intensive lifestyle intervention first, then Wegovy if lifestyle alone is insufficient. This aligns with clinical guidelines but requires insurance coverage or significant out-of-pocket spending.

When insurance covers Ozempic and when it doesn't

Insurance coverage for Ozempic depends on the patient's diagnosis, the specific insurance plan, and whether the prescription is written for an FDA-approved indication.

Medicare Part D: Covers Ozempic for type 2 diabetes. Does not cover Ozempic (or any medication) for weight loss due to statutory exclusion. Copay varies by plan but typically ranges from $35 to $150 per month under the 2026 Inflation Reduction Act insulin and diabetes medication cost-sharing caps.

Medicaid: Coverage varies by state. Most states cover Ozempic for diabetes with prior authorization. Some states (California, New York, Massachusetts) cover GLP-1 agonists for obesity under specific criteria, but coverage is for Wegovy or Saxenda, not off-label Ozempic.

Commercial insurance: Highly variable. Tier 2 or tier 3 formulary placement is common for diabetes, requiring prior authorization to confirm A1C ≥7.0% and inadequate control on metformin. Off-label coverage for weight loss is rare. Some plans explicitly exclude coverage if the diagnosis code is obesity (E66.x) rather than diabetes (E11.x).

Self-pay: Ozempic's list price is $935.77 per month (4 weekly doses). Manufacturer coupon (Ozempic Savings Card) reduces copay to $25 per month for commercially insured patients, but the coupon is not valid for Medicare, Medicaid, or self-pay patients. Actual self-pay cost is $900 to $950 per month at most pharmacies.

Compounded semaglutide: Not covered by any insurance. Self-pay only, typically $300 to $500 per month depending on dose and pharmacy. Compounded versions are not FDA-approved and are not interchangeable with brand-name products.

The coverage landscape creates perverse incentives. A patient with BMI 38 and A1C 6.2% (prediabetes) has no insurance coverage for semaglutide despite being at high risk for diabetes and cardiovascular disease. The same patient with A1C 6.6% (diabetes) qualifies for full coverage. This threshold effect drives some patients to delay lifestyle intervention in hopes of crossing into diabetes range to gain coverage, which is the opposite of optimal preventive care.

The decision framework: Ozempic vs Wegovy vs compounded semaglutide

Choose brand-name Ozempic if:

• You have type 2 diabetes with A1C ≥7.0%
• Your insurance covers Ozempic with acceptable copay
• You have established cardiovascular disease and want the proven MACE reduction benefit
• You prefer FDA-approved medication and are not concerned about the 0.4 mg dose difference vs Wegovy

Choose brand-name Wegovy if:

• Your primary goal is weight loss and you do not have diabetes
• Your BMI is ≥30 or ≥27 with comorbidities
• Your insurance covers Wegovy or you can afford $1,300+ per month self-pay
• You want the highest FDA-approved semaglutide dose (2.4 mg)

Choose compounded semaglutide if:

• You do not have insurance coverage for brand-name products
• You are willing to use a non-FDA-approved formulation to reduce cost
• You understand that compounded medications have not undergone the same safety and efficacy review as brand-name drugs
• Your provider is comfortable prescribing compounded GLP-1 agonists and monitoring appropriately

Do not use semaglutide (any formulation) if:

• You have a personal or family history of medullary thyroid carcinoma or MEN 2
• You have a history of severe pancreatitis
• You are pregnant, breastfeeding, or planning pregnancy within 2 months
• You have severe gastroparesis or diabetic gastroparesis
• You have a history of severe hypersensitivity reaction to semaglutide

The decision is not purely medical. Cost, insurance coverage, and personal preference around FDA approval status all factor in. A patient with diabetes, good insurance coverage, and preference for brand-name medication should choose Ozempic. A patient with obesity, no diabetes, and willingness to pay out-of-pocket should choose Wegovy or compounded semaglutide depending on budget.

FAQ

What is Ozempic FDA-approved to treat? Ozempic is FDA-approved for two indications: improving blood sugar control in adults with type 2 diabetes, and reducing the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with type 2 diabetes and established heart disease. It is not FDA-approved for weight loss.

Can doctors prescribe Ozempic for weight loss? Yes. Off-label prescribing is legal and common in clinical practice. Providers can prescribe Ozempic for weight loss in non-diabetic patients, but insurance typically will not cover off-label use, and patients pay out-of-pocket or use compounded alternatives.

What is the difference between Ozempic and Wegovy? Both contain semaglutide. Ozempic is approved for type 2 diabetes at doses up to 2.0 mg weekly. Wegovy is approved for chronic weight management at 2.4 mg weekly. The active ingredient is identical; the difference is dosing and FDA indication.

Does Ozempic lower A1C? Yes. Clinical trials show Ozempic lowers A1C by 1.5 to 2.0 percentage points on average. In the SUSTAIN-1 trial, 72 to 74% of patients achieved A1C below 7.0% after 30 weeks on Ozempic.

How much weight do people lose on Ozempic? In diabetic patients, Ozempic 1.0 mg produces average weight loss of 10 to 12 pounds over 6 months. In non-diabetic patients, weight loss is slightly higher, averaging 12 to 15 pounds at the same dose. Wegovy at 2.4 mg produces 15% body weight loss (30+ pounds for a 200-pound person).

Does Ozempic prevent heart attacks? In patients with type 2 diabetes and established cardiovascular disease, Ozempic reduces the risk of major cardiovascular events by 26% compared to placebo. This benefit has not been demonstrated in patients without diabetes or without prior cardiovascular disease.

Is Ozempic approved for prediabetes? No. Ozempic is approved only for type 2 diabetes, not prediabetes. Some providers prescribe it off-label for patients with prediabetes and obesity, but this is not an FDA-approved use and insurance typically does not cover it.

Can you take Ozempic if you don't have diabetes? Medically, yes, if prescribed by a provider. Legally, off-label prescribing is permitted. Practically, insurance will not cover it, so patients pay out-of-pocket or use compounded semaglutide. Wegovy is the FDA-approved option for non-diabetic patients seeking weight loss.

How long does it take for Ozempic to lower blood sugar? Blood sugar reduction begins within 1 to 2 weeks of starting Ozempic. Maximum A1C reduction occurs after 12 to 16 weeks at a stable dose. Providers typically check A1C at 3-month intervals to assess response.

Does Ozempic work for type 1 diabetes? No. Ozempic is not approved for type 1 diabetes and should not be used in type 1 diabetic patients. GLP-1 agonists work by enhancing insulin secretion from pancreatic beta cells, which are absent or non-functional in type 1 diabetes.

What conditions does Ozempic treat besides diabetes? Officially, only type 2 diabetes and cardiovascular risk reduction in diabetic patients with heart disease. Investigationally, semaglutide is being studied for NASH, obstructive sleep apnea, Alzheimer's disease, and addiction, but none of these uses are FDA-approved.

Can Ozempic cause thyroid cancer? Semaglutide caused thyroid C-cell tumors in rodent studies at exposures 2 to 8 times higher than human therapeutic doses. No cases of medullary thyroid carcinoma have been definitively attributed to semaglutide in humans, but the medication carries a boxed warning and is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.

Sources

1. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
2. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
3. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
6. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021.
7. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
8. Newsome PN et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. New England Journal of Medicine. 2021.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
11. FDA. Ozempic (semaglutide) injection prescribing information. 2017 (revised 2023).
12. FDA. Wegovy (semaglutide) injection prescribing information. 2021 (revised 2024).
13. IQVIA Institute for Human Data Science. Use of GLP-1 agonists in the United States: trends and implications. 2023.
14. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology. 2019.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly and Company. Qsymia is a registered trademark of Vivus. Contrave is a registered trademark of Currax Pharmaceuticals. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.